TABLE 2

Clinical profile of the subjects with I164T and R112C mutation

Case subjectI164T mutation
R112C mutation
Control subjects* Mean (SE)
123456789123
Age (years)52595961735065678248608361.5 (0.4)
SexMMMMMFFFFMMMM/F = 437/216
Plasma adiponectin (μg/ml)0.42.82.72.60.91.84.42.00.51.32.51.26.9 (0.2)
M = 6.0 (0.2)
F = 8.6 (0.4)
BMI (kg/m2)27.029.225.425.623.845.734.125.021.722.329.025.324.5 (0.2)
Systolic blood pressure (mmHg)150170120180142166144158190105130106132 (0.7)
Diastolic blood pressure (mmHg)1101168010080110789210055808875 (0.5)
Antihypertensive drug (yes/no)yesyesyesyesyesyesyesyesyesnoyesno
Total cholesterol (mg/dl)268208213236184316284247274243203226200 (1.6)
Triglycerides (mg/dl)38737212679134333235267302145331140157 (6.2)
HDL cholesterol (mg/dl)23375473343247473478345449 (0.7)
Antihyperlipidemic drug (yes/no)noyesyesnonoyesyesyesnononono
Fasting plasma glucose (mg/dl)10410529914897308114120296109112147114 (1.7)
HbA1c (%)4.96.86.96.35.514.45.95.811.15.15.28.16.0 (0.1)
Antidiabetic drug (yes/no)yesnoyesyesnoyesnoyesyesnonoyes
Diabetes or IGTDMIGTDMDMIGTDMDMDMDMDM
Atherosclerotic diseasesAPAPCVAMIAPAPAPAP
  • *

    * Subjects without mutations in adiponectin gene. AP, angina pectoris; CVA, cerebrovascular accident; DM, diabetes; IGT, impaired glucose tolerance; MI, myocardial infarction.